文献速递胸部肿瘤消化系统肿瘤支持与姑息治疗

通过靶向所有KRAS突变体拓展精准肿瘤学的应用范围

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.
PubMed 文献 · Cancer Discov · 2022-01-01

KRAS是最常突变的癌基因,约七分之一的癌症中携带KRAS突变。等位基因特异性KRASG12C抑制剂正在改变KRASG12C突变非小细胞肺癌和结直肠癌的治疗范式。本文综述了正在积极研究的等位基因特异性和泛KRAS抑制策略及其潜在用途。

要点

  • 突变选择性KRASG12C抑制剂仅覆盖约13.6%的KRAS驱动癌症。
  • 泛KRAS药物有望覆盖KRASG12D、G12V、G13D、G12R、G12A突变及KRAS野生型扩增癌症。
  • 未来KRAS药物分为突变选择性药物和泛KRAS治疗药物两类。

核心结论

  • 需要广泛的KRAS药物库来全面攻克KRAS驱动癌症,未来两类KRAS药物为突变选择性药物和泛KRAS治疗药物。

研究设计与样本

  • 综述,回顾正在积极研究的等位基因特异性和泛KRAS抑制策略及其潜在用途。

主要发现

  • KRAS是最常突变的癌基因,约七分之一的癌症中携带KRAS突变。
  • 等位基因特异性KRASG12C抑制剂正在改变KRASG12C突变非小细胞肺癌和结直肠癌患者的治疗范式。
  • 突变选择性KRASG12C抑制剂靶向所有KRAS驱动癌症中的约13.6%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: KRAS is the most frequently mutated oncogene, harboring mutations in approximately one in seven cancers. Allele-specific KRASG12C inhibitors are currently changing the treatment paradigm for patients with KRASG12C-mutated non-small cell lung cancer and colorectal cancer. The success of addressing a previously elusive KRAS allele has fueled drug discovery efforts for all KRAS mutants. Pan-KRAS drugs have the potential to address broad patient populations, including KRASG12D-, KRASG12V-, KRASG13D-, KRASG12R-, and KRASG12A-mutant or KRAS wild-type-amplified cancers, as well as cancers with acquired resistance to KRASG12C inhibitors. Here, we review actively pursued allele-specific and pan-KRAS inhibition strategies and their potential utility. SIGNIFICANCE: Mutant-selective KRASG12C inhibitors target a fraction (approximately 13.6%) of all KRAS-driven cancers. A broad arsenal of KRAS drugs is needed to comprehensively conquer KRAS-driven cancers. Conceptually, we foresee two future classes of KRAS medicines: mutant-selective KRAS drugs targeting individual variant alleles and pan-KRAS therapeutics targeting a broad range of KRAS alterations.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Hofmann MH, Gerlach D, Misale S, et al. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discov. 2022. PMID: 35046095. doi:10.1158/2159-8290.CD-21-1331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。